Background: The antioxidant enzyme is a selenoprotein that transports selenium in blood and maintains its levels in peripheral tissues. Aberrant expression is strongly linked to the development of some tumors. However, there is a scarcity of studies examining the pan-cancer expression patterns and prognostic relevance of .
Methods: expression levels in normal tissues and multiple tumors were analyzed using TCGA, CCLE, GTEx, UALCAN and HPA databases. Forest plots and KM survival curves were utilized to evaluate the correlation between expression and the outcome of tumor patients. The prognostic value of in LGG was assessed utilizing the CGGA datasets, and that in STAD was tested by TCGA and GEO databases. A nomogram was then constructed to predict OS in STAD using R software. Additionally, the impact of on post-chemoradiotherapy OS in patients with LGG and STAD was evaluated using the KM method. The multiplicative interaction of expression, chemotherapy and radiotherapy on STAD and LGG was analyzed using logistic regression models. The correlation of with the immune infiltration, immune neoantigens and MMR genes were investigated in TCGA cohort.
Results: exhibited downregulation across 21 tumor types, including STAD, with its decreased expression significantly associated with improved OS, DFS, PFS and DSS. Conversely, in LGG, low levels of expression were indicative of a poorer prognosis. Univariate and multivariate Cox models further identified as an independent predictor of STAD, and a nomogram based on expression and other independent factors showed high level of predictive accuracy. Moreover, low expression and chemotherapy prolonged the survival of STAD. In LGG patients, chemoradiotherapy, and chemotherapy, and and chemoradiotherapy may improve prognosis. Our observations reveal a notable connection between and immune infiltration, immune neoantigens, and MMR genes.
Conclusions: The variations in expression are linked to the controlling tumor development and could act as a promising biomarker that impacts the prognosis of specific cancers like STAD and LGG.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11170152 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2024.e32271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.
Heliyon
November 2024
Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, 710061, China.
Article Synopsis
- CD73 is an important molecule involved in immune regulation and its role in the tumor microenvironment was investigated using multiple cancer databases, revealing elevated levels in several cancer types like esophageal carcinoma and glioblastoma.
- The study found that high CD73 expression was often linked to poor overall survival in various cancers such as breast and lung cancers, although in some cases (like kidney and uterine cancers), high expression was associated with better outcomes.
- Additionally, tumors with high CD73 expression showed increased immune scores and positive correlations with immune cell infiltration, indicating a complex relationship between CD73 and the immune response in tumors.
Evaluating KLHDC8A as a biomarker for glioma: impact on survival and proliferation through the Wnt/β-catenin pathway.
Discov Oncol
November 2024
Research Center, the Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Glioma is one of the most common malignant tumors and shows a high metastasis rate and poor prognosis. KLHDC8A has been implicated in several cancers, but its role in glioma and its potential as a biomarker remain unclear. We conducted a pan-cancer analysis of KLHDC8A using multiple databases and assessed its expression levels, survival associations, and diagnostic utility.
View Article and Find Full Text PDFPan-cancer analysis identifies the oncogenic role of in human cancers.
Aging (Albany NY)
November 2024
Department of Orthopedics, Changsha Hospital, Xiangya Medical College, Central South University, Changsha 410005, China.
Objective: To investigate expression, prognosis, immune cell infiltration of C () in cancer.
Methods: We used TIMER and GEPIA datasets to analyze the differential expression of in multiple tumors. GEPIA and Kaplan-Meier plotter databases were utilized to observe the prognostic significance of in cancer.
Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.
Sci Rep
October 2024
The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Lymphocyte activating gene-3 (LAG3) is a distinctive T cell co-receptor that is expressed on the surface of lymphocytes. It plays a special inhibitory immune checkpoint role due to its unique domain and signaling pattern. Our aim is to explore the correlation between LAG3 in cancers and physiological processes related to a range of cancers, as well as build LAG3-related immunity and prognostic models.
View Article and Find Full Text PDFPan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy.
Front Mol Biosci
August 2024
Department of Medical Microbiology and Immunology, School of Basic Medical Sciences, Dali University, Dali, Yunnan, China.
Article Synopsis
- FAM110B is a protein that might play a role in cancer growth and is found in special structures within cells called centrosomes and mitotic spindles.
- Researchers looked at how FAM110B behaves in different types of cancers and normal tissues using various data sources and tools.
- The study suggests that FAM110B could be important for understanding how tumors interact with the immune system, and it might help predict how well certain cancer treatments will work.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!